Background: Juvenile idiopathic arthritis (JIA) is a group of chronic arthropathies of unknown cause affecting children under 16yrs, and is the most common childhood inflammatory rheumatic diagnosis, affecting 1 in 1,000 UK children. In recent years great advances in dissecting the genetic basis of JIA have been made. In one landmark study, conducted on the two most common subtypes (oligoarthritis and RF-negative polyarthritis), 17 susceptibility loci were identified at genome-wide significance (p-value<5x10 À08 ) with a further 11 reaching suggestive significance (p-value<1x10 À06 ). 1 The findings from this study were the results of a large international collaboration using the ImmunoChip array, a custom-made array targeting 186 known loci in 12 autoimmune diseases. However, one limitation to the aforementioned study was that the analysis was limited to the selected loci; large genome-wide studies are therefore needed. Aims: To identify novel genetic loci associated with disease susceptibility using a large cohort of UK JIA cases. Methods: Whole-genome genotyping data was generated using four platforms (Illumina) in UK cases ($ half were also on previous ImmunoChip study). Following stringent quality control common variants to all four platforms were extracted from the individual datasets before merging together. Imputation was performed using the Haplotype Reference Consortium panel on the Michigan Imputation Server using Minimac3 software. SNPs with imputation accuracy (r 2 >0.5), minor allele frequency>1% and Hardy-Weinberg p-value>1x10
À03 were retained for analysis. Association was conducted using logistic regression; using the top three principal components as covariates. Bioinformatics analysis was performed using in-house Capture Hi-C data, 2 to study long-range interactions, to elucidate the potential function of the associated SNPs. Results: Post-QC, 2,585 JIA cases and 5,181 controls were available for analysis. Analysis conducted within oligoarthritis and RF-negative polyarthritis cases, (n ¼ 1,590) confirmed nine previously identified JIA risk loci and identified 13 potentially novel regions. Of these, rs7874896, an intergenic SNP located near TNFSF8 was the most strongly associated (p-value 3.67x10
À07
). Further investigation of this SNP using Capture Hi-C data yielded a potentially interesting interaction with the promoter region of TNFSF8 within T-and B-cell lines, suggesting this SNP may be regulating the expression of TNFSF8, a cytokine belonging to the tumour necrosis factor (TNF) ligand family. Conclusions: This study represents the largest GWAS conducted in JIA to date and our preliminary results have identified novel associations with the most common subtypes of the disease.
Background: Juvenile-Onset Systemic Lupus Erythematosus (JSLE) is a multi-system autoimmune disease causing severe kidney damage, known as lupus nephritis (LN) 1 . LN is initiated by glomerular immune complex formation which induces inflammatory responses leading to proteinuria 2 . Active LN has been correlated with elevated levels of certain urinary protein biomarkers, including alpha-1-acid glycoprotein (AGP), transferrin (TF), caeruloplasmin (CP), lipocalin-type prostaglandin D2 synthase (L-PGDS), neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) 3 . It is unclear whether the biomarker origin is exclusively systemic or whether the resident renal cells also contribute to their production. Aim: To investigate whether the glomerular endothelial cells (GEnCs) are able to produce these biomarkers. Methods: Conditionally immortalized human GEnCs (ciGEnCs) were treated for 4, 24 and 48 hours with 5% sera from JSLE patients with active LN (renal BILAG A or B; n ¼ 4-5), inactive LN (renal BILAG D or E; n ¼ 4-5) and paediatric healthy controls (n ¼ 4-5). ciGEnCs in standard culture medium were used as negative controls. Furthermore, ciGEnCs were stimulated with IFN-a (10 ng/ml) or LPS (1 mg/ml). 68-27.57) and untreated ciGEnCs (1.04; 0.45-1.63) for VCAM-1 mRNA. ciGEnC -sera treatments did not induce significant differences in biomarker expression, secretion or production. Conclusions: The lack of a robust effect of patient sera on the mRNA biomarker expression could be attributed to the administration of immunosuppressive medications to JSLE patients. The intra-renal role of these biomarkers remains to be elucidated.
